Literature DB >> 15201684

Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension.

Michael Halank, Stephan Miehlke, Gert Hoeffken, Alexander Schmeisser, Matthias Schulze, Ruth H Strasser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15201684     DOI： 10.1097/01.tp.0000122420.86904.89

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  14 in total

Review 1.  Portopulmonary hypertension.

Authors:  Michael Halank; Ralf Ewert; Hans-Juergen Seyfarth; Gert Hoeffken
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

2.  Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan.

Authors:  Christian M Kähler; Ivo Graziadei; Helene Vogelsinger; Susanna Desole; Katharina Cima; Wolfgang Vogel
Journal:  Wien Klin Wochenschr       Date:  2011-03-31       Impact factor: 1.704

Review 3.  Medical management of chronic liver diseases (CLD) in children (part II): focus on the complications of CLD, and CLD that require special considerations.

Authors:  Mortada H F El-Shabrawi; Naglaa M Kamal
Journal:  Paediatr Drugs       Date:  2011-12-01       Impact factor: 3.022

Review 4.  [Pulmonary affection in advanced liver disease - hepatepulonary syndrome and portopulmonary hypertension].

Authors:  Kerstin Herzer; Felix Post; Ali Canbay; Guido Gerken
Journal:  Med Klin (Munich)       Date:  2011-01-16

5.  Outcomes of liver transplantation for porto-pulmonary hypertension in model for end-stage liver disease era.

Authors:  Reena J Salgia; Nathan P Goodrich; Heather Simpson; Robert M Merion; Pratima Sharma
Journal:  Dig Dis Sci       Date:  2014-02-21       Impact factor: 3.199

6.  Portopulmonary hypertension.

Authors:  Sarfraz Saleemi
Journal:  Ann Thorac Med       Date:  2010-01       Impact factor: 2.219

Review 7.  Pulmonary vascular complications of liver disease.

Authors:  Jason S Fritz; Michael B Fallon; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

Review 8.  Management of portopulmonary hypertension: new perspectives.

Authors:  Luigi Mancuso; Francesca Scordato; Michela Pieri; Eliana Valerio; Andrea Mancuso
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

9.  Intraoperative pulmonary hypertension occurred in an asymptomatic patient with pre-existent liver cirrhotic and portal hypertension.

Authors:  Ling Lu; Feng Zhang; Xiang-Cheng Li; Guo-Qiang Li; Chuan-Yong Zhang; Xue-Hao Wang
Journal:  World J Gastroenterol       Date:  2008-12-21       Impact factor: 5.742

Review 10.  [Pulmonary complications of liver cirrhosis: hepatopulmonary syndrome, portopulmonary hypertension and hepatic hydrothorax].

Authors:  M Halank; C P Strassburg; M M Hoeper
Journal:  Internist (Berl)       Date:  2010-03       Impact factor: 0.743
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.